Ticker

Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program

Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption

Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 155,110 shares, an increase of 795.6% from the June 30th total of 17,320 shares. Approximately 14.3% of the shares of the stock are sold short. Based

Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate

Silo Pharma Incs (NASDAQ:SILO) announced on Tuesday that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices Inc.'s (NASDAQ:AMD) AI Developer Program, providing access to cloud computing credits, AI development tools, training resources, and a global developer network aimed at accelerating the platform's growth.